Top Ten: Weekend roundup: Wells Fargo and its auditor | The back-pain racket | Going back to the movies

Trump's war on regulation Includes big tradeoffs
August 19, 2017
The Wall Street Journal: Mnuchin rejects calls to resign and defends Trump
August 20, 2017

MarketWatch rounded up 10 of its most interesting topics over the past week.

1. Wells Fargo leaves egg on its auditor’s face

Will more board-level heads roll at Wells Fargo & Co..

WFC, -0.23%

as fresh cases emerge of the bank’s abuse of loan and deposit customers? The scandals may also mean big trouble for KPMG, which has functioned as Wells Fargo’s outside auditor for 85 years.

2. Be wary of wasteful, useless back-pain treatments

Chronic back pain is a really common problem, but there’s a $100 billion industry of devices and treatments that are, for the most part, ineffective, with some causing harm, based on Cathryn Jakobson Ramin, the author of “Crooked: Outwitting the Back Pain Industry and Getting on the Road to Recovery.” Jakobson clarifies in an interview with Emma Court that for many people, the pain results from a lack of exercise.

3. MoviePass goes for the magical number

Netflix Inc..

NFLX, +0.27%

 has proven that a $10 monthly subscription price can revolutionize an industry. And now MoviePass is enabling you to view one movie a day at 33,000 theaters across the U.S., for the exact monthly price. MoviePass CEO Mitch Lowe clarifies the Organization’s business model in an interview with Trey Williams.

4. Wal-Mart is making a big bet against Amazon

It is conventional wisdom that nobody could beat or even compete with Amazon.com Inc..

AMZN, -0.22%

in online retail, but Wal-Mart Stores Inc..

WMT, -0.49%

 

 said its second-quarter online sales rose by 60 percent from a year before. The company has deep pockets and has made a long-term commitment to continue building its online services, as Tonya Garcia reports.

5. Tepper says economy fears are overblown…

Have you responded to the years of daily headlines saying the stock exchange is way overvalued? David Tepper, an extremely successful hedge-fund manager, says there’s no comparison (in a great way) between this market and outrageously high valuations of the dot-com bubble that ended in 2000.

6. …But this benchmark index appears cheaper than it really is

The benchmark small-cap Russell 2000 index

RUT, -0.08%

 

  is actually trading much higher relative to earnings than you might think, Mark Hulbert explains.

7. This can help your teenager build wealth

Setting up a Roth IRA for your child as soon as he or she begins working can help build a huge nest egg at a comparatively young age, according to Liz Weston.

8. Good earnings season, but Trump’s ‘failure’ could mean trouble ahead

It has been a great earnings season, with S&P 500

SPX, -0.18%

  companies’ earnings per share up 10 percent, but a comprehensive look at the results reveals strain on U.S. consumers. Meanwhile, the inability of President Trump and the Republican majorities in Congress to make progress on tax reform, health-care reform, regulatory relief or infrastructure spending are causing corporate managers to limit their spending on business growth. This points to a stifling of wage growth, based on Tomi Kilgore and Ciara Linnane.

Read: Pay attention to these economic warning signs

9. These stocks have been unloved, but may be bargains

With another earnings season nearly complete, Jeff Reeves looks at five companies that seem to be on the rebound.

10. Crowdfunding makes it much easier to select individual real-estate investments

Crowdfunding isn’t only for raising money from donors. Additionally, it allows investors to be highly selective as they participate in individual real-estate projects. Charles Clinton explains ways to get involved in this fast growing segment of this real-estate industry and the pros and cons of each approach.

Want more from MarketWatch? Take a look at our Personal Finance Daily or other newsletters, and get the latest news, personal finance and investing information.

More from MarketWatch

More Coverage

Comments are closed.

Buy now